Rock Springs Capital

Portfolio Co Investors 2026 for Rock Springs Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Rock Springs Capital accounts for 23 tracked companies with verified cap-table data, 23 of which disclose round sizes totalling $8.2B. The median disclosed raise is $172M, and the largest is Kymera Therapeutics at $3B, ahead of Treeline Biosciences ($1.1B) and Immunocore ($665M).

The names that recur most often on these co-invested cap tables are Rock Springs Capital (23 companies), Surveyor Capital (5 companies), Bain Capital Life Sciences (4 companies), Janus Henderson Investors (4 companies), OrbiMed (4 companies), RA Capital Management (4 companies). By latest disclosed round, the market skews Series C (8), Series B (7), Series A (3), Series E (1).

Best funded Rock Springs Capital companies

  1. Kymera Therapeutics — $3B (latest: Series C)
  2. Treeline Biosciences — $1.1B (latest: Series A)
  3. Immunocore — $665M (latest: Series C)
  4. Affinivax — $359M (latest: Series C)
  5. Honor — $325M (latest: Series E)
  6. FogPharma — $323M (latest: Series D)
  7. Genesis HealthCare — $280M (latest: Series B)
  8. Apollo Therapeutics — $260M (latest: Series C)
  9. Coherus Biosciences — $220M (latest: Series C)
  10. Verve Therapeutics — $216M (latest: Series B)
  11. ESCAPE Bio — $184M (latest: Series C)
  12. Amylyx Pharmaceuticals — $172M (latest: Series C)
  13. Fusion Pharmaceuticals — $171M (latest: Series B)
  14. Disc Medicine — $153M (latest: Series B)
  15. BioTheryX — $127M

Rock Springs Capital Management LP — related firms and companies (56)

Rock Springs Capital Management LP profile · All research reports